MedTrace Logo

The Effects of Nicotine on Cognition in Schizophrenia

NCT00383747 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-04-28

Study results available
· View outcomes & findings →

Summary

Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We will evaluate the effects of transdermal nicotine compared with placebo for attentional impairments in non-smokers with schizophrenia and controls.

Conditions

Interventions

DRUG

transdermal nicotine patch

14mg transdermal nicotine application

DRUG

Transdermal Nicotine Patch

14mg transdermal nicotine application

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • North Suffolk Mental Health Association

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • A E EVINS, MD MPH · Massachusetts General Hosptal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383747 on ClinicalTrials.gov